Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $165.31
    -2.09 (-1.25%)

    Market Cap: $16.94B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neurocrine Biosciences Inc (NBIX) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Neurocrine Biosciences (NBIX) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Neurocrine Biosciences reported EPS of $2.78, above the $1.95 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -6.84%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.02
    Range$1.34 - $2.56
    29 analysts
    Revenue Consensus
    $1.11B
    Range$1.03B - $1.26B
    27 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.73
    Range$2.32 - $3.11
    6 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$2.65+2.9%
    60d ago$2.65+2.9%
    30d ago$2.65+2.9%
    7d ago$2.74-0.3%
    Current$2.73
    Revenue Consensus
    $1.07B
    Range$1.03B - $1.09B
    8 analysts

    Next Report

    NBIX has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.4% above the $1.88 reported for the quarter ended Dec 31, 2025.

    NBIX Earnings Call

    The latest NBIX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, NBIX beat 17, missed 22 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.12B, up 40.9% from $794.90M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.78$1.95N/A+42.56%Beat+28.1%171 up, 1 downNov 2, 2026$1.12B
    Jun 30, 2026$2.36$1.88-$1.90 - $3.16+25.53%Beat+43.0%152 up, 1 downJul 30, 2026$959.00M
    Mar 31, 2026$1.94$1.70$1.42 - $2.17+14.12%Beat+177.1%132 up, 5 downMay 5, 2026$814.50M
    Dec 31, 2025$1.88$2.30$2.04 - $2.81-18.26%Miss+11.2%151 up, 10 downFeb 11, 2026$805.50M
    Sep 30, 2025$2.17$2.07$1.78 - $2.54+4.83%Beat+19.9%162 up, 3 downOct 28, 2025$794.90M
    Jun 30, 2025$1.65$1.50$1.34 - $1.80+10.00%Beat+1.2%151 up, 3 downJul 30, 2025$687.50M
    Mar 31, 2025$0.70$1.09$0.15 - $1.65-35.78%Miss-41.7%141 up, 10 downMay 5, 2025$572.60M
    Dec 31, 2024$1.69$1.93$0.50 - $2.35-12.44%Miss+9.7%133 up, 2 downFeb 6, 2025$627.70M
    Sep 30, 2024$1.81$1.82$1.26 - $2.12-0.55%Miss+17.5%196 up, 0 downOct 30, 2024$622.10M
    Jun 30, 2024$1.63$1.53$0.27 - $1.71+6.54%Beat+30.4%173 up, 0 downAug 1, 2024$590.20M
    Mar 31, 2024$1.20$1.29$0.18 - $1.77-6.98%MissN/A186 up, 4 downMay 1, 2024$515.30M
    Dec 31, 2023$1.54$1.51N/A+1.99%Beat+24.2%196 up, 1 downFeb 7, 2024$515.20M
    Sep 30, 2023$1.54$1.33$0.35 - $1.35+15.79%Beat+42.6%186 up, 0 downOct 31, 2023$498.80M
    Jun 30, 2023$1.25$1.12N/A+11.61%Beat+48.8%1710 up, 0 downAug 1, 2023$452.70M
    Mar 31, 2023-$0.51$0.74-$0.85 - $1.11-168.92%Miss-270.0%191 up, 0 downMay 3, 2023$420.40M
    Dec 31, 2022$1.24$1.44$0.73 - $2.45-13.89%Miss+3000.0%174 up, 1 downFeb 6, 2023$412.00M
    Sep 30, 2022$1.08$1.12$0.21 - $1.16-3.57%Miss+68.8%187 up, 0 downNov 1, 2022$387.90M
    Jun 30, 2022$0.84$0.89N/A-5.62%Miss+33.3%154 up, 0 downAug 4, 2022$378.20M
    Mar 31, 2022$0.30$0.59$0.19 - $0.70-49.15%Miss-38.8%194 up, 0 downMay 4, 2022$310.60M
    Dec 31, 2021$0.04$0.88-$0.83 - $1.06-95.45%Miss-95.6%192 up, 1 downFeb 11, 2022$312.00M
    Sep 30, 2021$0.64$0.80$0.06 - $1.06-20.00%Miss-34.0%18N/ANov 1, 2021$296.00M
    Jun 30, 2021$0.63$0.76N/A-17.11%Miss-55.6%18N/AAug 3, 2021$288.90M
    Mar 31, 2021$0.49$0.72-$0.03 - $0.81-31.94%Miss-40.2%19N/AMay 5, 2021$236.60M
    Dec 31, 2020$0.91$0.90-$0.59 - $0.93+1.11%Beat+160.0%20N/AFeb 4, 2021$247.90M
    Sep 30, 2020$0.97$1.25-$0.65 - $1.43-22.40%Miss+73.2%20N/ANov 9, 2020$258.50M
    Jun 30, 2020$1.42$1.02$0.17 - $1.38+39.22%Beat+163.0%19N/AAug 3, 2020$302.40M
    Mar 31, 2020$0.82$0.64$0.05 - $0.87+28.13%BeatN/A22N/AMay 6, 2020$237.10M
    Dec 31, 2019$0.35$0.75$0.23 - $0.95-53.33%Miss+84.2%18N/AFeb 4, 2020$244.10M
    Sep 30, 2019$0.56$0.64$0.23 - $0.84-12.50%Miss+7.7%19N/ANov 4, 2019$222.10M
    Jun 30, 2019$0.54$0.25-$1.30 - $0.64+116.00%BeatN/A17N/AJul 29, 2019$183.50M
    Mar 31, 2019-$1.12-$0.89-$1.39 - -$0.02-25.84%MissN/A14N/AApr 29, 2019$138.40M
    Dec 31, 2018$0.19$0.19$0.05 - $0.440.00%In line+171.4%15N/AFeb 5, 2019$131.45M
    Sep 30, 2018$0.52$0.49$0.02 - $0.64+6.12%BeatN/A12N/ANov 5, 2018$151.76M
    Jun 30, 2018-$0.07-$0.18-$0.33 - -$0.12+61.11%BeatN/A9N/AJul 31, 2018$96.91M
    Mar 31, 2018-$0.47-$0.30-$0.46 - -$0.16-56.67%MissN/A10N/AApr 30, 2018$71.09M
    Dec 31, 2017$0.07$0.18-$0.05 - $0.39-61.11%MissN/A13N/AFeb 13, 2018$94.52M
    Sep 30, 2017-$0.13-$0.53-$0.75 - -$0.15+75.47%BeatN/A12N/ANov 1, 2017$60.77M
    Jun 30, 2017-$0.68-$0.65-$0.77 - -$0.60-4.62%MissN/A12N/AAug 3, 2017$6.33M
    Mar 31, 2017-$0.90-$0.72N/A-25.00%MissN/AN/AN/AMay 9, 2017N/A
    Dec 31, 2016-$0.51-$0.55N/A+7.27%BeatN/AN/AN/AFeb 14, 2017$15.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.40, up 1.1% from the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.40+1.1%
    Dec 31, 2024$6.33+65.7%
    Dec 31, 2023$3.82+10.4%
    Dec 31, 2022$3.46+92.2%
    Dec 31, 2021$1.80-56.3%
    Dec 31, 2020$4.12+1148.5%
    Dec 31, 2019$0.33+94.1%
    Dec 31, 2018$0.17N/A
    Dec 31, 2017-$1.64N/A
    Dec 31, 2016-$1.62N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,200 words across 31 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,24731
    2026Q2Jun 30, 20266,93230
    2026Q1Mar 31, 20267,63229
    2025Q4Dec 31, 20258,57624
    2025Q3Sep 30, 20258,15430
    2025Q2Jun 30, 20258,19129
    2025Q1Mar 31, 20258,59222
    2024Q4Dec 31, 20249,82026

    2026Q3 Earnings Call

    Opening remarks

    Todd Tushla Vice President of Investor Relations Thank you. And happy Monday, wherever it is that you may be. Welcome to Neurocrine Biosciences Third Quarter 2026 Earnings Call. Joining me on today's call are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Eiry Roberts, Chief Medical Officer; and Samir Siddhanti, Chief Business Officer. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. Following prepared remarks, we'll be happy to take your questions. With that, I'll hand the call off to Kyle.

    Kyle Gano CEO Good afternoon, everyone. Nearly 2 years ago, on my first earnings call as CEO, I shared my optimism about Neurocrine's future and the significant opportunities ahead. Today, that confidence has only grown stronger as I remain deeply confident in our ability to drive sustained growth and create long-term value for our shareholders. Our strategy to build a leading biopharmaceutical company is grounded in execution and delivering meaningful results. In the third quarter, we generated record net product sales of more than $1.1 billion and record profitability. These results underscore the strength of our diversified portfolio of 3 first-in-class medicines and our growing ability to reach and serve more patients than ever before. This momentum positions us well to drive continued growth across INGREZZA, CRENESSITY and VYKAT XR in 2027 and beyond. The strength of our growing commercial business and financial position also enables us to continue investing in our industry-leading pipeline. With several important clinical milestones anticipated in 2027, including Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we believe Neurocrine is approaching a potentially transformative period, one that could further expand our pipeline, strengthen our long-term growth prospects and extend our impact on patients. Overall, Neurocrine's third quarter performance exemplifies the strength of our strategy, the discipline of our execution and the significant opportunity ahead to create long-term value. As we close out the year, we look forward to hosting our 2026 R&D Day in New York City on December 15. The event will feature a VYKAT XR panel discussion with Dr.

    Frequently Asked Questions About NBIX

    When is Neurocrine Biosciences's next earnings date?

    Neurocrine Biosciences's next earnings report is expected for Feb 9, 2027.

    Did NBIX beat earnings estimates last quarter?

    Yes. Neurocrine Biosciences reported EPS of $2.78 for the quarter ended Sep 30, 2026, above the $1.95 estimate, a 42.56% surprise.

    What EPS do analysts expect from NBIX next quarter?

    The consensus EPS estimate for Neurocrine Biosciences for the quarter ending Dec 31, 2026 is $2.02 from 29 analysts, with estimates from $1.34 to $2.56.

    How often does NBIX beat earnings estimates?

    Neurocrine Biosciences beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.82%.